Showing 1233 results
-
Press Release /Novartis is spinning off three mid stage clinical assets to Mereo for further development in exchange for equity Novartis will have a stake in the success of the development of these compounds…
-
Press Release /Dr. Joerg Reinhardt, Chairman of the Novartis Board of Directors, will serve as Chairman of the Foundation Board of trustees New trustees also include Professor Peter Piot of the London School…
-
Press Release /Approval is based on pivotal Phase II study in which objective response rate (ORR) in patients with laBCC was 58%; responses were durable[1] Basal cell carcinoma, the most common form of skin…
-
Press Release /CHMP positive opinion for EU approval of Tafinlar and Mekinist combination in BRAF V600 mutation-positive melanoma, the most aggressive type of skin cancer FDA grants priority review for…
-
Press Release /If approved, Revolade would be the first treatment option in its class in the EU for certain patients with SAA Approximately 40% of SAA patients unresponsive to initial immunosuppressive…
-
Press Release /Sales, core[1] operating income and core EPS grew (cc[1]) for continuing operations[2] in Q2: Net sales amounted to USD 12.7 billion (-5%, +6% cc) Operating income was USD 2.3…
-
Press Release /Croissance des ventes, du résultat opérationnel core[1] et du BPA core (tcc[1]) des activités poursuivies[2] au T2: Le chiffre d'affaires net s'est élevé à USD 12,7 milliards (-5%, +6% tcc). Le…
-
Press Release /Die fortzuführenden Geschäftsbereiche[2] steigern im zweiten Quartal den Umsatz, das operative Kernergebnis[1] und den Kerngewinn pro Aktie (kWk[1]): Der Nettoumsatz beläuft sich auf USD 12,7…
-
Press Release /WHO prequalified Coartem® 80/480mg is the first and only high strength malaria treatment available for donor-funded public sector procurement Coartem® 80/480mg reduces the pill burden for…
-
Press Release /First in the world approval brings hope of longer life and fewer hospitalizations for millions of Americans with heart failure with reduced ejection fraction Entresto is the first and only treatment…